Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Split-course Hypo-CCRT Following Induction Chemo-immunotherapy in LA-ESCC
NCT06020885Phase 1Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2023
- Primary completion
- Oct 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of toripalimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Sun Yat-sen University. Primary endpoint: Maximum Tolerated Fraction Dose at 6 months. Started Aug 2023; status: active, not recruiting.
02
Drugs
toripalimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06020885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06020885.